Matt Hoffman, Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He executive produces the NeurologyLive Mind Moments® podcast, and hosted the Medical World News show Deep Dive. Follow him on Twitter @byMattHoffman or email him at [email protected]
The RightEye Vision System is able to use eye-tracking technology to identify ocular tremors that persist for patients with Parkinson disease and might not only aid in easing the process of diagnosis but could potentially allow for the earlier identification of the disease.
The anti-CGRP treatment from Teva was associated with reductions in the use of migraine-specific headache medication, migraine-associated symptoms, and any acute headache medication use compared to placebo.
The novel formulation of edaravone, which was approved in May 2017, will be assessed in a cohort of 150 patients with amyotrophic lateral sclerosis for 48 weeks of treatment.
With Theranica’s Nerivio Migra acute migraine device named a top invention of the year, three experts in migraine shared their insight into its clinical application in the early days of its availability, with varying experiences.
The label update includes adjustments to the withdrawal risk section and a new subsection for its use in specific populations.
Midazolam nasal spray CIV, marketed under the brand name Nayzilam, is expected to become available in retail pharmacies early next month after its approval for the treatment of intermittent, stereotypic episodes of frequent seizure activity in epilepsy.
The use of cerebrospinal neurofilament light chain and TAR DNA‐binding protein 43 in tandem may offer stronger biomarkers for amyotrophic lateral sclerosis diagnosis, with NfL also offering a measure of disease progression.
After receiving a complete response letter from the FDA in January, Sunovion Pharmaceuticals has resubmitted its NDA for apomorphine sublingual film, also known as APL-130277.
The FDA set a PDUFA date for risdiplam of May 24, 2020. The full 12-month data from the SUNFISH trial are expected to be presented at an upcoming medical meeting.
SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.
The chief medical officer at SK Life Science discussed what the sodium channel antagonist will offer those treating partial-onset seizures.
The mesenchymal stem cell-neurotrophic factor cells met the primary safety end point and displayed early but promising signs of efficacy, prompting excitement among investigators for moving forward with phase 3 study.
SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.
Findings of a phase 2 assessment has suggested that otaplimastat can be safely administered in patients with stroke who are being treated with recombinant tissue plasminogen activator and is realistic to be further studied.
The investigational new drug application for OWP Pharmaceuticals’ first-ever liquid formulation of topiramate, intended to offer a new delivery alternative for the therapy in epilepsy and migraine treatment, has been approved.
An analysis of ACHIEVE II suggests that the oral CGRP antagonist from Allergan provides significant pain freedom and relief of the most bothersome symptoms for adults with migraine for at least one dose assessed.
SK Life Science’s investigational agent cenobamate has shown an ability to significantly reduce focal-onset seizures in doses of 100, 200, and 400-mg compared to placebo. An NDA was filed for the therapy in early 2019.
Pooled analysis from 3 studies of more than 1000 patients with migraine suggest that galcanezumab (Emgality, Eli Lilly) has good cardiovascular safety and is not linked with vasoconstriction or an increase in cardiovascular adverse events.
The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.
An automated deep neural network, SpikeNet, performed at or above the accuracy, sensitivity, and specificity of fellowship-trained clinical experts in identifying interictal epileptiform discharges.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Amaal Starling, MD.
Interictal epileptiform discharges on EEG readings had a positive predictive value of 77.3% and a negative predictive value of 70 %, with a sensitivity of detecting spikes prior to epilepsy of 85%.
The director of Centers for Neuropsychology and Neuroscience Research and Traumatic Brain Injury Research at Kessler Foundation spoke to the use of strategy training and how it mirrors real-life situations for patients with MS and TBI.
Study findings have shown sustained improvements in seizure-freedom rates and functional outcomes in a cohort of adults that mirror prior findings in pediatric populations.
The 2019 update to the 2018 guidelines clarifies prior recommendations and takes into consideration new clinical trial data to offer a comprehensive guide for treatment, from symptom onset through 2 weeks after acute ischemic stroke.
The comprehensive aggressive migraine protocol (CAMP), combining DHE infusion and multidisciplinary care, significantly reduced headache intensity and frequency among other measures in a small group of patients.
The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine provided her perspective on the differences in OSA prevalence for men and women and how adherence to CPAP remains a challenge.
The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared his unique perspective on spinal cord injury and the work he and colleagues are doing to alleviate its challenges.
UCB’s intranasal midazolam spray (Nayzilam), an FDA-approved therapy for seizure clusters, has shown success and rapid efficacy in status epilepticus, with treatment effect occurring approximately 4 to 5 minutes post-administration.
A new analysis from the phase 3 HALO development program showed that Teva’s CGRP inhibitor fremanezumab (Ajovy) separated from placebo by Day 2 posttreatment, suggesting not only rapid clinical improvement, but the potential to positively impact treatment adherence.
